Singapore bans hormonal and surgical treatment for gender dysphoria in minors
Singapore has joined a growing group of countries imposing stricter conditions on the medical treatment of gender dysphoria in young people. On 5 May 2026, the Ministry of Health sent healthcare providers a circular containing the first official treatment guidelines for gender dysphoria in children and adolescents. The key decision: no hormonal or surgical treatments may be offered to anyone under the age of 18.
What the guidelines specifically regulate
The circular, signed by Director-General of Health Professor Kenneth Mak, states that young people under 18 diagnosed with gender dysphoria may not be offered hormonal or surgical treatment. Cross-sex hormones remain prohibited until the age at which a person is legally considered an adult in Singapore: 21. An exception may be possible for those aged 18 to 21, but only after approval by a special review panel, the Treatment Review Panel. Puberty blockers are not recommended in the guidelines, citing a lack of evidence regarding their long-term safety and effectiveness. Psychological support is designated as the first and primary treatment option, with a diagnostic process that, according to the guidelines, may take twelve to eighteen months before further steps are considered.
The ministry’s rationale
The ministry justifies the decision by referring to the well-known figures concerning the development of gender dysphoria in children: eighty to ninety-five percent of prepubertal children with gender dysphoria are said to grow out of it, according to historical research when no medical intervention takes place. The guidelines also warn that puberty blockers may actually ‘lock in’ a young person’s gender-related distress rather than provide time for reflection—the opposite of the so-called ‘pause button’ argument typically used to defend these drugs. Why that metaphor is misleading is explained on puberteitsblokkers.nl. In doing so, Singapore aligns itself with the conclusions of the British Cass Review of 2024, which described the evidence base for puberty blockers in minors as remarkably weak.
Part of a broader international trend
With these guidelines, Singapore joins a series of countries that have backed away in recent years from the model of early medicalisation. The United Kingdom stopped the routine provision of puberty blockers outside research settings, Sweden restricted treatment to strictly controlled research settings through the Karolinska Hospital, and Finland opted for psychosocial treatment as the first step through the COHERE guidelines. The course correction in Sweden, Finland and the United Kingdom is described on transtijd.nl. Singapore is therefore the first Asian country to enshrine a similarly explicit and cautious approach in law. The decision could set a precedent for the region: neighbouring countries that have so far lacked their own guidelines may draw on the Singaporean model when developing them.
What this means for young people and parents
For Singaporean families, the guidelines primarily mean that the route to medical transition for minors is now formally closed, with psychological support becoming the legally mandated focus. Supporters of the guidelines point to uncertainty about the long-term effects on fertility and brain development as reasons for caution. Critics of this approach generally argue that a strict ban could make it more difficult for young people with persistent gender dysphoria to access care. As in Europe, this debate in Singapore is also taking place against the backdrop of a growing number of countries that consider the scientific basis for early medical transition too weak.
Source:
Edward Jansen
Genderinfo.nl editorial team
Frequently asked questions
Read also
On Coming Out Day, the rainbow flag will fly at the building of the Dutch House of Representatives (Tweede Kamer) for the first time. The House decided this on 8 October 2026 by 90 votes to 36, after the Presidium had withdrawn an earlier decision following a procedural objection from the SGP.
At Therapy First’s annual conference in New York in early October 2026, it became clear just how divided even the cautious side of the gender debate is. Therapy First remains committed to a therapy-first approach that leaves room for later medical steps; Genspect categorically rejects medical transition for minors — and the departure of a critical social worker exposes the tension between the two.
New Australian teaching materials and government guidelines replace “boys have penises” with “bodies with penises” and explain reproduction without human figures. A retired sexologist warns that this leaves children without the vocabulary to talk about their own bodies.